PURPOSE: The RET protooncogene plays a crucial role in neural crest development; accordingly, mutations of RET cause MEN2A and familial medullary thyroid carcinoma, while the expression deregulation of RET is involved in the pathophysiology of glioblastoma multiforme (GBM) and pancreatic cancer (PDAC). The aim of this study was to evaluate if germline variants of the RET protooncogene are associated with GBM, pancreatic cancer and gastric cancer (GC). METHODS: Genomic DNA from peripheral blood was isolated from 100 patients with GBM, 65 patients with GC and 54 patients with PDAC. The coding sequence of RET promoter, exon 2 and exon 13 was amplified. Sequence variations at -5 and -1 in the promotor and in exon 2 were determined through a LightCycler assay, and analysis of exon 13 was carried out by genomic sequencing. RESULTS: There was no significant association of the RET-promoter or exon 2 genotypes with the phenotype in the different populations, although there was an increase of the GG genotype of the -5G>A variant in all cancers compared to controls. Sequencing of exon 13 identified mutation c.2372A>T in codon 791 (Y791F) in heterozygous state in one of 100 GBM patients, in two of 65 patients with gastric cancer, in two of 54 PDAC patients and in none of the controls. CONCLUSIONS: Although our data did not reach significance in our small cohorts, we cannot rule out the involvement of the -5G promoter allele and the c.2372A>T mutation in the development of the aforementioned tumours.
PURPOSE: The RET protooncogene plays a crucial role in neural crest development; accordingly, mutations of RET cause MEN2A and familial medullary thyroid carcinoma, while the expression deregulation of RET is involved in the pathophysiology of glioblastoma multiforme (GBM) and pancreatic cancer (PDAC). The aim of this study was to evaluate if germline variants of the RET protooncogene are associated with GBM, pancreatic cancer and gastric cancer (GC). METHODS: Genomic DNA from peripheral blood was isolated from 100 patients with GBM, 65 patients with GC and 54 patients with PDAC. The coding sequence of RET promoter, exon 2 and exon 13 was amplified. Sequence variations at -5 and -1 in the promotor and in exon 2 were determined through a LightCycler assay, and analysis of exon 13 was carried out by genomic sequencing. RESULTS: There was no significant association of the RET-promoter or exon 2 genotypes with the phenotype in the different populations, although there was an increase of the GG genotype of the -5G>A variant in all cancers compared to controls. Sequencing of exon 13 identified mutation c.2372A>T in codon 791 (Y791F) in heterozygous state in one of 100 GBM patients, in two of 65 patients with gastric cancer, in two of 54 PDAC patients and in none of the controls. CONCLUSIONS: Although our data did not reach significance in our small cohorts, we cannot rule out the involvement of the -5G promoter allele and the c.2372A>T mutation in the development of the aforementioned tumours.
Authors: Guido Fitze; Mandy Schierz; Jan Bredow; Hans D Saeger; Dietmar Roesner; Hans K Schackert Journal: Ann Surg Date: 2002-11 Impact factor: 12.969
Authors: Z Songyang; K L Carraway; M J Eck; S C Harrison; R A Feldman; M Mohammadi; J Schlessinger; S R Hubbard; D P Smith; C Eng Journal: Nature Date: 1995-02-09 Impact factor: 49.962
Authors: Hirozumi Sawai; Yuji Okada; Kevork Kazanjian; Joseph Kim; Sascha Hasan; Oscar J Hines; Howard A Reber; Dave S B Hoon; Guido Eibl Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: I Berndt; M Reuter; B Saller; K Frank-Raue; P Groth; M Grussendorf; F Raue; M M Ritter; W Höppner Journal: J Clin Endocrinol Metab Date: 1998-03 Impact factor: 5.958
Authors: Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs Journal: Thyroid Date: 2014-06-06 Impact factor: 6.568
Authors: Rodrigo A Toledo; Roxanne Hatakana; Delmar M Lourenço; Susan C Lindsey; Cleber P Camacho; Marcio Almeida; José V Lima; Tomoko Sekiya; Elena Garralda; Michel S Naslavsky; Guilherme L Yamamoto; Monize Lazar; Osorio Meirelles; Tiago J P Sobreira; Maria Lucia Lebrao; Yeda A O Duarte; John Blangero; Mayana Zatz; Janete M Cerutti; Rui M B Maciel; Sergio P A Toledo Journal: Endocr Relat Cancer Date: 2014-11-25 Impact factor: 5.678